Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory response

Experimental Neurology

Volumn 212, Issue 2, 2008, Pages 522-531

  Iravani, Mahmoud M ^a   Sadeghian, Mona ^a   Leung, Clement C M ^a   Tel, Banu C ^a   Rose, Sarah ^a   Schapira, Anthony H ^b   Jenner, Peter ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Glial cells; Inducible nitric oxide synthase (iNOS); Lipopolysaccharide; Parkinson's disease; Pramipexole; Striatum; Substantia nigra

Indexed keywords

AMPHETAMINE; BIOLOGICAL MARKER; LIPOPOLYSACCHARIDE; PRAMIPEXOLE; TYROSINE 3 MONOOXYGENASE; UBIQUITIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN NERVE CELL; CELL COUNT; CELL DEATH; CELL DEGENERATION; CELL LOSS; CONTINUOUS INFUSION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; IMMUNOCOMPETENT CELL; INFLAMMATION; MALE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; ROTATION; SUBSTANTIA NIGRA; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; UPREGULATION;

AMPHETAMINE; ANIMALS; BEHAVIOR, ANIMAL; BENZOTHIAZOLES; CELL COUNT; CELL DEATH; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE UPTAKE INHIBITORS; DRUG INTERACTIONS; INFLAMMATION; INJECTIONS, SUBCUTANEOUS; LIPOPOLYSACCHARIDES; MALE; MOTOR ACTIVITY; NEURONS; RATS; RATS, WISTAR; SUBSTANTIA NIGRA; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 47349086173     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2008.04.037     Document Type: Article

References (52)

1. Ahlskog J.E. I can't get no satisfaction: still no neuroprotection for Parkinson disease. Neurology 69 (2007) 1476-1477
2. Breidert T., Callebert J., Heneka M.T., Landreth G., Launay J.M., and Hirsch E.C. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J. Neurochem. 82 (2002) 615-624
3. Bozzi Y., and Borrelli E. Dopamine in neurotoxicity and neuroprotection: what do D2 receptors have to do with it?. Trends Neurosci. 29 (2006) 167-174
4. Calzi F., Bellasio R., Guiso G., Caccia S., and Tacconi M.T. Effect of piribedil and its metabolite, S584, on brain lipid peroxidation in vitro and in vivo. Eur. J. Pharmacol. 338 (1997) 185-190
5. Carvey P.M., McGuire S.O., and Ling Z.D. Neuroprotective effects of D3 dopamine receptor agonists. Parkinsonism Relat. Disord. 7 (2001) 213-223
6. Cassarino D.S., Fall C.P., Smith T.S., and Bennett Jr. J.P. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J. Neurochem. 71 (1998) 295-301
7. Clarke C.E. Neuroprotection and pharmacotherapy for motor symptoms in Parkinson's disease. Lancet Neurol. 3 (2004) 466-474
8. Danzeisen R., Schwalenstoecker B., Gillardon F., Buerger E., Krzykalla V., Klinder K., Schild L., Hengerer B., Ludolph A.C., Dorner-Ciossek C., and Kussmaul L. Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-lpropylamino-benzathiazole dihydrochloride]. J. Pharmacol. Exp. Ther. 316 (2006) 189-199
9. Du F., Li R., Huang Y., Li X., and Le W. Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons. Eur. J. Neurosci. 22 (2005) 2422-2430
10. Ferger B., Teismann P., and Mierau J. The dopamine agonist pramipexole scavenges hydroxyl free radicals induced by striatal application of 6-hydroxydopamine in rats: an in vivo microdialysis study. Brain Res. 883 (2000) 216-223
11. Finotti N., Castagna L., Moretti A., and Marzatico F. Reduction of lipid peroxidation in different rat brain areas after cabergoline treatment. Pharmacol. Res. 42 (2000) 287-291
12. Fujita Y., Izawa Y., Ali N., Kanematsu Y., Tsuchiya K., Hamano S., Tamaki T., and Yoshizumi M. Pramipexole protects against H2O2-induced PC12 cell death. Naunyn Schmiedeberg's Arch. Pharmacol. 372 (2006) 257-266
13. Gao H.M., Liu B., Zhang W., and Hong J.S. Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol. Sci. 24 (2003) 395-401
14. Gassen M., Glinka Y., Pinchasi B., and Youdim M.B. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur. J. Pharmacol. 308 (1996) 219-225
15. Gille G., Rausch W.D., Hung S.T., Moldzio R., Janetzky B., Hundemer H.P., Kolter T., and Reichmann H. Pergolide protects dopaminergic neurons in primary culture under stress conditions. J. Neural. Transm. 109 (2002) 633-643
16. Gille G., Rausch W.D., Hung S.T., Moldzio R., Ngyuen A., Janetzky B., Engfer A., and Reichmann H. Protection of dopaminergic neurons in primary culture by lisuride. J. Neural. Transm. 109 (2002) 157-169
17. Gomez-Vargas M., Nishibayashi-Asanuma S., Asanuma M., Kondo Y., Iwata E., and Ogawa N. Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits lipid peroxidation in different regions of the rat brain. Brain Res. 790 (1998) 202-208
18. Grunblatt E., Mandel S., Gassen M., and Youdim M.B. Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity. J. Neural. Transm. Suppl. 55 (1999) 57-70
19. Gu M., Iravani M.M., Cooper J.M., King D., Jenner P., and Schapira A.H. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J. Neurochem. 91 (2004) 1075-1081
20. Hall E.D., Andrus P.K., Oostveen J.A., Althaus J.S., and VonVoigtlander P.F. Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Res. 742 (1996) 80-88
21. Herrera A.J., Castano A., Venero J.L., Cano J., and Machado A. The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol. Dis. 7 (2000) 429-447
22. Hung A.Y., and Schwarzschild M.A. Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility?. Curr. Opin. Neurol. 20 (2007) 477-483
23. Iida M., Miyazaki I., Tanaka K., Kabuto H., Iwata-Ichikawa E., and Ogawa N. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res. 838 (1999) 51-59
24. Iravani M.M., Kashefi K., Mander P., Rose S., and Jenner P. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience 110 (2002) 49-58
25. Iravani M.M., Haddon C.O., Cooper J.M., Jenner P., and Schapira A.H. Pramipexole protects against MPTP toxicity in non-human primates. J. Neurochem. 96 (2006) 1315-1321
26. Iravani M.M., Leung C.C., Sadeghian M., Haddon C.O., Rose S., and Jenner P. The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation. Eur. J. Neurosci. 22 (2005) 317-330
27. Izumi Y., Sawada H., Yamamoto N., Kume T., Katsuki H., Shimohama S., and Akaike A. Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity. Eur. J. Pharmacol. 557 (2007) 132-140
28. Joyce J.N., and Millan M.J. Dopamine D3 receptor agonists for protection and repair in Parkinson's disease. Curr. Opin. Pharmacol. 7 (2007) 100-105
29. Joyce J.N., Presgraves S., Renish L., Borwege S., Osredkar T., Hagner D., Replogle M., PazSoldan M., and Millan M.J. Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole. Exp. Neurol. 184 (2003) 393-407
30. Kitamura Y., Kosaka T., Kakimura J.I., Matsuoka Y., Kohno Y., Nomura Y., and Taniguchi T. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. Mol. Pharmacol. 54 (1998) 1046-1054
31. Le W.D., Jankovic J., Xie W., and Appel S.H. Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection. J. Neural. Transm. 107 (2000) 1165-1173
32. Luna-Medina R., Cortes-Canteli M., Sanchez-Galiano S., Morales-Garcia J.A., Martinez A., Santos A., and Perez-Castillo A. NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: potential therapeutic role in brain disorders. J. Neurosci. 27 (2007) 5766-5776
33. McGeer E.G., and McGeer P.L. The role of anti-inflammatory agents in Parkinson's disease. CNS Drugs 21 (2007) 789-797
34. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 284 (2000) 1931-1938
35. Piercey M.F. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin. Neuropharmacol. 21 (1998) 141-151
36. Presgraves S.P., Borwege S., Millan M.J., and Joyce J.N. Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells. Exp. Neurol. 190 (2004) 157-170
37. Qian L., Tan K.S., Wei S.J., Wu H.M., Xu Z., Wilson B., Lu R.B., Hong J.S., and Flood P.M. Microglia-mediated neurotoxicity is inhibited by morphine through an opioid receptor-independent reduction of NADPH oxidase activity. J. Immunol. 179 (2007) 1198-1209
38. Qin L., Liu Y., Wang T., Wei S.J., Block M.L., Wilson B., Liu B., and Hong J.S. NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. J. Biol. Chem. 279 (2004) 1415-1421
39. Qin L., Wu X., Block M.L., Liu Y., Breese G.R., Hong J.S., Knapp D.J., and Crews F.T. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 55 (2007) 453-462
40. Sayeed I., Parvez S., Winkler-Stuck K., Seitz G., Trieu I., Wallesch C.W., Schonfeld P., and Siemen D. Patch clamp reveals powerful blockade of the mitochondrial permeability transition pore by the D2-receptor agonist pramipexole. FASEB J. 20 (2006) 556-558
41. Schapira A.H. Disease modification in Parkinson's disease. Lancet Neurol. 3 (2004) 362-368
42. Schapira A.H., Bezard E., Brotchie J., Calon F., Collingridge G.L., Ferger B., Hengerer B., Hirsch E., Jenner P., Le Novere N., Obeso J.A., Schwarzschild M.A., Spampinato U., and Davidai G. Novel pharmacological targets for the treatment of Parkinson's disease. Nat. Rev. Drug Discov. 5 (2006) 845-854
43. Schapira A.H., and Olanow C.W. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 291 (2004) 358-364
44. Takashima H., Tsujihata M., Kishikawa M., and Freed W.J. Bromocriptine protects dopaminergic neurons from levodopa-induced toxicity by stimulating D(2)receptors. Exp. Neurol. 159 (1999) 98-104
45. Teismann P., Tieu K., Choi D.K., Wu D.C., Naini A., Hunot S., Vila M., Jackson-Lewis V., and Przedborski S. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 5473-5478
46. Van Kampen J.M., and Robertson H.A. A possible role for dopamine D3 receptor stimulation in the induction of neurogenesis in the adult rat substantia nigra. Neuroscience 136 (2005) 381-386
47. Vincenzi F.F., and Hinds T.R. Pramipexole has antioxidant properties and inhibits lipid peroxidation. Proc. West. Pharmacol. Soc. 41 (1998) 43-46
48. Wahner A.D., Bronstein J.M., Bordelon Y.M., and Ritz B. Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology 69 (2007) 1836-1842
49. Whone A.L., Watts R.L., Stoessl A.J., Davis M., Reske S., Nahmias C., Lang A.E., Rascol O., Ribeiro M.J., Remy P., Poewe W.H., Hauser R.A., and Brooks D.J. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann. Neurol. 54 (2003) 93-101
50. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.K., Ischiropoulos H., and Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22 (2002) 1763-1771
51. Yoshioka M., Tanaka K., Miyazaki I., Fujita N., Higashi Y., Asanuma M., and Ogawa N. The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals. Neurosci. Res. 43 (2002) 259-267
52. Zou L., Xu J., Jankovic J., He Y., Appel S.H., and Le W. Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice. Neurosci. Lett. 281 (2000) 167-170